Monitoring the immune response in sepsis: A rational approach to administration of immunoadjuvant therapies

Current Opinion in Immunology

Volumn 25, Issue 4, 2013, Pages 477-483

  Venet, Fabienne ^a   Lukaszewicz, Anne Claire ^b   Payen, Didier ^b   Hotchkiss, Richard ^c   Monneret, Guillaume ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; IMMUNOLOGICAL ADJUVANT; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RECOMBINANT INTERLEUKIN 7; UNCLASSIFIED DRUG;

ACINETOBACTER; ANTIGEN EXPRESSION; BURN; CANDIDA; CYTOMEGALOVIRUS; DENDRITIC CELL; DRUG EFFICACY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL MONITORING; INJURY; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEPSIS; SEPTIC SHOCK; VIRUS INFECTION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; SEPSIS;

EID: 84884140248     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.05.006     Document Type: Review

References (59)

1. Levy M.M., Artigas A., Phillips G.S., Rhodes A., Beale R., Osborn T., Vincent J.L., Townsend S., Lemeshow S., Dellinger R.P. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 2012, 12:919-924.
2. Hotchkiss R.S., Monneret G., Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13:260-268.
3. Torgersen C., Moser P., Luckner G., Mayr V., Jochberger S., Hasibeder W.R., Dunser M.W. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 2009, 108:1841-1847.
4. Landelle C., Lepape A., Francais A., Tognet E., Thizy H., Voirin N., Timsit J.F., Monneret G., Vanhems P. Nosocomial infection after septic shock among intensive care unit patients. Infect Control Hosp Epidemiol 2008, 29:1054-1065.
5. Limaye A.P., Kirby K.A., Rubenfeld G.D., Leisenring W.M., Bulger E.M., Neff M.J., Gibran N.S., Huang M.L., Santo Hayes T.K., Corey L., et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, 300:413-422.
6. Chiche L., Forel J.M., Roch A., Guervilly C., Pauly V., Allardet-Servent J., Gainnier M., Zandotti C., Papazian L. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med 2009, 37:1850-1857.
7. Luyt C.E., Combes A., Deback C., Aubriot-Lorton M.H., Nieszkowska A., Trouillet J.L., Capron F., Agut H., Gibert C., Chastre J. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007, 175:935-942.
8. Christou N.V., Meakins J.L., Gordon J., Yee J., Hassan-Zahraee M., Nohr C.W., Shizgal H.M., MacLean L.D. The delayed hypersensitivity response and host resistance in surgical patients, 20 years later. Ann Surg 1995, 222:534-546. discussion 546-538.
9. Landelle C., Lepape A., Voirin N., Tognet E., Venet F., Bohe J., Vanhems P., Monneret G. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med 2010, 36:1859-1866.
10. Lukaszewicz A.C., Grienay M., Resche-Rigon M., Pirracchio R., Faivre V., Boval B., Payen D. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009, 37:2746-2752.
11. Grimaldi D., Louis S., Pene F., Sirgo G., Rousseau C., Claessens Y.E., Vimeux L., Cariou A., Mira J.P., Hosmalin A., et al. Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock. Intensive Care Med 2011, 37:1438-1446.
12. Cavaillon J.M., Adrie C., Fitting C., Adib-Conquy M. Reprogramming of circulatory cells in sepsis and SIRS. J Endotoxin Res 2005, 11:311-320.
13. Biswas S.K., Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009, 30:475-487.
14. Carson W.F., Cavassani K.A., Dou Y., Kunkel S.L. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 2011, 6:273-283.
15. Opal S.M. New perspectives on immunomodulatory therapy for bacteraemia and sepsis. Int J Antimicrob Agents 2010, 36S2:S70-S73.
16. Fullerton J.N., Singer M. Organ failure in the ICU: cellular alterations. Semin Respir Crit Care Med 2011, 32:581-586.
17. Boomer J.S., To K., Chang K.C., Takasu O., Osborne D.F., Walton A.H., Bricker T.L., Jarman S.D., Kreisel D., Krupnick A.S., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
18. Monneret G., Venet F., Pachot A., Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14:64-78.
19. Delano M.J., Thayer T., Gabrilovich S., Kelly-Scumpia K.M., Winfield R.D., Scumpia P.O., Cuenca A.G., Warner E., Wallet S.M., Wallet M.A., et al. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J Immunol 2011, 186:195-202.
20. Pillay J., Kamp V.M., van Hoffen E., Visser T., Tak T., Lammers J.W., Ulfman L.H., Leenen L.P., Pickkers P., Koenderman L. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 2012, 122:327-336.
21. Derive M., Bouazza Y., Alauzet C., Gibot S. Myeloid-derived suppressor cells control microbial sepsis. Intensive Care Med 2012, 38:1040-1049.
22. Brudecki L., Ferguson D.A., McCall C.E., El Gazzar M. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect Immun 2012, 80:2026-2034.
23. von Muller L., Klemm A., Durmus N., Weiss M., Suger-Wiedeck H., Schneider M., Hampl W., Mertens T. Cellular immunity and active human cytomegalovirus infection in patients with septic shock. J Infect Dis 2007, 196:1288-1295.
24. Forel J.M., Chiche L., Thomas G., Mancini J., Farnarier C., Cognet C., Guervilly C., Daumas A., Vely F., Xeridat F., et al. Phenotype and functions of natural killer cells in critically-ill septic patients. PLoS ONE 2012, 7:e50446.
25. Deknuydt F., Roquilly A., Cinotti R., Altare F., Asehnoune K. An in vitro model of mycobacterial granuloma to investigate the immune response in brain-injured patients. Crit Care Med 2013, 41:245-254.
26. Berres M.L., Schnyder B., Yagmur E., Inglis B., Stanzel S., Tischendorf J.J., Koch A., Winograd R., Trautwein C., Wasmuth H.E. Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. Liver Int 2009, 29:536-543.
27. Payen D., Faivre V., Lukaszewicz A.C., Villa F., Goldberg P. Expression of monocyte human leukocyte antigen-DR in relation with sepsis severity and plasma mediators. Minerva Anestesiol 2009, 75:484-493.
28. Poehlmann H., Schefold J.C., Zuckermann-Becker H., Volk H.D., Meisel C. Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit Care 2009, 13:R119.
29. Guisset O., Dilhuydy M.S., Thiebaut R., Lefevre J., Camou F., Sarrat A., Gabinski C., Moreau J.F., Blanco P. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med 2007, 33:148-152.
30. Andre M.C., Gille C., Glemser P., Woiterski J., Hsu H.Y., Spring B., Keppeler H., Kramer B.W., Handgretinger R., Poets C.F., et al. Bacterial reprogramming of PBMCs impairs monocyte phagocytosis and modulates adaptive T cell responses. J Leukoc Biol 2012, 91:977-989.
31. Faivre V., Lukaszewicz A.C., Alves A., Charron D., Payen D., Haziot A. Human monocytes differentiate into dendritic cells subsets that induce anergic and regulatory T cells in sepsis. PLoS ONE 2012, 7:e47209.
32. Monneret G., Lepape A., Voirin N., Bohe J., Venet F., Debard A.L., Thizy H., Bienvenu J., Gueyffier F., Vanhems P. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006, 32:1175-1183.
33. Wolk K., Docke W.D., von Baehr V., Volk H.D., Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000, 96:218-223.
34. van Dissel J.T., van Langevelde P., Westendorp R.G., Kwappenberg K., Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998, 351:950-953.
35. Rose W.E., Eickhoff J.C., Shukla S.K., Pantrangi M., Rooijakkers S., Cosgrove S.E., Nizet V., Sakoulas G. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J Infect Dis 2012, 206:1604-1611.
36. Demaret J., Walencik A., Jacob M.C., Timsit J.F., Venet F., Lepape A., Monneret G. Inter-laboratory assessment of flow cytometric monocyte HLA-DR expression in clinical samples. Cytometry B Clin Cytom 2013, 84:59-62.
37. Docke W.D., Hoflich C., Davis K.A., Rottgers K., Meisel C., Kiefer P., Weber S.U., Hedwig-Geissing M., Kreuzfelder E., Tschentscher P., et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005, 51:2341-2347.
38. Orozco H., Arch J., Medina-Franco H., Pantoja J.P., Gonzalez Q.H., Vilatoba M., Hinojosa C., Vargas-Vorackova F., Sifuentes-Osornio J. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Arch Surg 2006, 141:150-153.
39. Meisel C., Schefold J.C., Pschowski R., Baumann T., Hetzger K., Gregor J., Weber-Carstens S., Hasper D., Keh D., Zuckermann H., et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:640-648.
40. Turina M., Dickinson A., Gardner S., Polk H.C. Monocyte HLA-DR and interferon-gamma treatment in severely injured patients-a critical reappraisal more than a decade later. J Am Coll Surg 2006, 203:73-81.
41. Mohammad R.A. Use of granulocyte colony-stimulating factor in patients with severe sepsis or septic shock. Am J Health Syst Pharm 2010, 67:1238-1245.
42. Hall M.W., Knatz N.L., Vetterly C., Tomarello S., Wewers M.D., Volk H.D., Carcillo J.A. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 2011, 37:525-532.
43. Docke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., Volk H.D., Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997, 3:678-681.
44. MacLean L.D., Meakins J.L., Taguchi K., Duignan J.P., Dhillon K.S., Gordon J. Host resistance in sepsis and trauma. Ann Surg 1975, 182:207-217.
45. Venet F., Davin F., Guignant C., Larue A., Cazalis M.A., Darbon R., Allombert C., Mougin B., Malcus C., Poitevin-Later F., et al. Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 2010, 34:358-363.
46. Hotchkiss R.S., Nicholson D.W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6:813-822.
47. Venet F., Foray A.P., Villars-Mechin A., Malcus C., Poitevin-Later F., Lepape A., Monneret G. IL-7 restores lymphocyte functions in septic patients. J Immunol 2012, 189:5073-5081.
48. van de Veerdonk F.L., Mouktaroudi M., Ramakers B.P., Pistiki A., Pickkers P., van der Meer J.W., Netea M.G., Giamarellos-Bourboulis E.J. Deficient Candida-specific T-helper 17 response during sepsis. J Infect Dis 2012, 206:1798-1802.
49. Boomer J.S., Shuherk-Shaffer J., Hotchkiss R.S., Green J.M. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 2012, 16:R112.
50. Guignant C., Lepape A., Huang X., Kherouf H., Denis L., Poitevin F., Malcus C., Cheron A., Allaouchiche B., Gueyffier F., et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011, 15:R99.
51. Venet F., Filipe-Santos O., Lepape A., Malcus C., Poitevin-Later F., Grives A., Plantier N., Pasqual N., Monneret G Decreased T cell repertoire diversity in sepsis: a preliminary study. Crit Care Med 2013, 41:111-119.
52. Venet F., Chung C.S., Monneret G., Huang X., Horner B., Garber M., Ayala A Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 2008, 83:523-535.
53. Hotchkiss R.S., Opal S. Immunotherapy for sepsis-a new approach against an ancient foe. N Engl J Med 2010, 363:87-89.
54. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012, 366:2517-2519.
55. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
56. Lundstrom W., Fewkes N.M., Mackall C.L. IL-7 in human health and disease. Semin Immunol 2012, 24:218-224.
57. Unsinger J., Kazama H., McDonough J.S., Griffith T.S., Hotchkiss R.S., Ferguson T.A. Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism. J Immunol 2010, 184:6766-6772.
58. Unsinger J., Burnham C.A., McDonough J., Morre M., Prakash P.S., Caldwell C.C., Dunne W.M., Hotchkiss R.S. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 2012, 206:606-616.
59. Annane D. Improving clinical trials in the critically ill: unique challenge-sepsis. Crit Care Med 2009, 37:S117-S128.